Possis plummets on poor heart attack study data
This article was originally published in Clinica
A 480-patient, post-marketing study of Possis Medical's thrombus-busting AnjioJet catheter has failed to find evidence to support using the device routinely to reduce final infarct size in all heart attack patients.
You may also be interested in...
The director of adult immunizations at Johns Hopkins International Vaccine Access Center talks to Scrip about undertaking a massive COVID-19 vaccination effort in the US.
P&G’s oral care business drove 35% of total category market growth in the firm’s fiscal 2020 and exemplifies its growth strategy for all segments – grow entire categories rather than take competitors’ market share, says CFO Jon Moeller.
The Pink Sheet explains the procedures underpinning the UK’s emergency use authorization of the Pfizer/BioNTech COVID-19 vaccine.